{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:30:28Z","timestamp":1782113428437,"version":"3.54.5"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEG"],"DOI":"10.2147\/ceg.s351839","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T12:15:05Z","timestamp":1675944905000},"page":"11-19","source":"Crossref","is-referenced-by-count":7,"title":["Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-1435","authenticated-orcid":true,"given":"Prapassorn","family":"Thirasastr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":true,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"Heinrich","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","volume":"477","author":"Liang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/s41598-018-38028-x","volume":"9","author":"Nannini","year":"2019","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1758835919841946","DOI":"10.1177\/1758835919841946","volume":"11","author":"Mazzocca","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","volume":"120","author":"Napolitano","year":"2019","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.tips.2012.03.005","volume":"33","author":"Norman","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"ref12","first-page":"1091","volume":"2009","author":"Gajiwala","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/annonc\/mdp291","volume":"21","author":"Blay","year":"2010","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"44121","DOI":"10.18632\/oncotarget.17310","volume":"8","author":"Yeh","year":"2017","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"672500","DOI":"10.3389\/fonc.2021.672500","volume":"11","author":"Bauer","year":"2021","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/1078-0432.CCR-18-1858","volume":"25","author":"Gebreyohannes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref19","first-page":"1946","volume":"2017","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"E639","DOI":"10.1002\/onco.13674","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.21.00217","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"Serrano","year":"2019","journal-title":"Br J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1158\/0008-5472.CAN-18-3139","volume":"79","author":"Apsel Winger","year":"2019","journal-title":"Cancer Res"},{"key":"ref25","unstructured":"Heinrich M, von Mehren M, Jones RL, Bauer S, Kang Y. Avapritinib is highly active and well-tolerated in patients with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA. presented at Connective Tissue Oncology Society 2018 Annual Meeting; 2018; Rome, Italy."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"viii576","DOI":"10.1093\/annonc\/mdy299.002","volume":"29","author":"George","year":"2018","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"C077","DOI":"10.1158\/1535-7163.TARG-19-C077","volume":"18","author":"Chi","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"ref28","first-page":"OF1","volume":"2022","author":"Rose","year":"2022","journal-title":"Cancer Discov"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Jones RL, Gelderblom H, et al. INTRIGUE_A phase III_ randomized, open-label study to evaluate the efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor. Presented in ASCO Plenary Series: January Program; 2022.","DOI":"10.1200\/JCO.2022.40.36_suppl.359881"},{"key":"ref30","unstructured":"Mehren M, Heinrich M, George S, et al. Clinical benefit with ripretinib as \u22654th-line treatment in patients with advanced gastrointestinal stromal tumor: long-term update from the phase 3 INVICTUS study. Presented at CTOS 2021; November 10\u201313, 2021; 2021."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1200\/JCO.20.00522","volume":"38","author":"Janku","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2021.07.010","volume":"155","author":"George","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"Young","year":"1999","journal-title":"Eur, J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"11535","DOI":"10.1200\/JCO.2020.38.15_suppl.11535","volume":"38","author":"Heinrich","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87384","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T12:15:17Z","timestamp":1675944917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/emerging-data-on-the-safety-and-efficacy-of-ripretinib-for-the-treatme-peer-reviewed-fulltext-article-CEG"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/ceg.s351839","relation":{},"ISSN":["1178-7023"],"issn-type":[{"value":"1178-7023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}